Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Aclaris Therapeutics

08/05/2025 14:20

Aclaris Therapeutics Inc ACRS.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -24 cents.  The mean expectation of six analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -14 cents to -9 cents per share.

Revenue fell 39.3% to $1.46 million from a year ago; analysts expected $1.28 million.

Aclaris Therapeutics Inc's reported EPS for the quarter was a loss of 12 cents​.

The company reported a quarterly loss of $15.09 million.

Aclaris Therapeutics Inc shares had fallen by 18.3% this quarter and lost 49.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00

This summary was machine generated from LSEG data May 8 at 01:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.12
-0.12
Met
Dec. 31 2024
-0.22
-1.01
Missed
Sep. 30 2024
-0.01
-0.11
Missed
Jun. 30 2024
-0.20
-0.15
Beat